Revisiting the technical validation of tumour biomarker assays: How to open a Pandora's box

BMC Medicine

Volumn 9, Issue , 2011, Pages

  Marchiò, Caterina ^a   Dowsett, Mitch ^b,c   Reis Filho, Jorge S ^c  

^a UNIVERSITY OF TURIN   (Italy)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER;

BIOASSAY; BREAST CANCER; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; POLYMERASE CHAIN REACTION; SHORT SURVEY; TISSUE MICROARRAY; VALIDATION PROCESS; DIAGNOSTIC PROCEDURES; METHODOLOGY; NEOPLASM; NUCLEIC ACID AMPLIFICATION; REVIEW; STANDARD; VALIDATION STUDY;

CLINICAL LABORATORY TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; TUMOR MARKERS, BIOLOGICAL; VALIDATION STUDIES AS TOPIC;

EID: 79955077801     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-9-41     Document Type: Short Survey

References (29)

1. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95. 10.1067/mcp.2001.113989, 11240971, Biomarkers Definitions Working Group.
2. Diamandis EP, Hoffman BR, Sturgeon CM. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for the Use of Tumor Markers. Clin Chem 2008, 54:1935-1939. 10.1373/clinchem.2008.105494, 18801938.
3. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, Babaian R, Bast RC, Dowell B, Esteva FJ, Haglund C, Harbeck N, Hayes DF, Holten-Andersen M, Klee GG, Lamerz R, Looijenga LH, Molina R, Nielsen HJ, Rittenhouse H, Semjonow A, Shih I, Sibley P, Sölétormos G, Stephan C, Sokoll L, Hoffman BR, Diamandis EP, . National Academy of Clinical Biochemistry National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008, 54:e11-e79. 10.1373/clinchem.2008.105601, 19042984, National Academy of Clinical Biochemistry.
4. Sturgeon CM, Hoffman BR, Chan DW, Ch'ng SL, Hammond E, Hayes DF, Liotta LA, Petricoin EF, Schmitt M, Semmes OJ, Sölétormos G, van der Merwe E, Diamandis EP, . National Academy of Clinical Biochemistry National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. Clin Chem 2008, 54:e1-e10. 10.1373/clinchem.2007.094144, 18606634, National Academy of Clinical Biochemistry.
5. Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 2004, 4:309-314. 10.1038/nrc1322, 15057290.
6. Carden CP, Sarker D, Postel-Vinay S, Yap TA, Attard G, Banerji U, Garrett MD, Thomas GV, Workman P, Kaye SB, de Bono JS. Can molecular biomarker-based patient selection in phase I trials accelerate anticancer drug development?. Drug Discov Today 2010, 15:88-97. 10.1016/j.drudis.2009.11.006, 19961955.
7. Cummings J, Raynaud F, Jones L, Sugar R, Dive C. Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs. Br J Cancer 2010, 103:1313-1317. 10.1038/sj.bjc.6605910, 20924371.
8. Ransohoff DF. Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer 2005, 5:142-149. 10.1038/nrc1550, 15685197.
9. Diamandis EP. Re: Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2003, 95:489-491. 10.1093/jnci/95.6.489, 12644546.
10. Miller K, Ibrahim M, Barnett S, Jasani B. Technical aspects of predictive and prognostic markers in breast cancer: what UK NEQAS data show. Curr Diagn Pathol 2007, 13:135-149.
11. Bussolati G, Leonardo E. Technical pitfalls potentially affecting diagnoses in immunohistochemistry. J Clin Pathol 2008, 61:1184-1192. 10.1136/jcp.2007.047720, 18326011.
12. Yaziji H, Barry T. Diagnostic immunohistochemistry: what can go wrong?. Adv Anat Pathol 2006, 13:238-246. 10.1097/01.pap.0000213041.39070.2f, 16998317.
13. Leong AS. Pitfalls in diagnostic immunohistology. Adv Anat Pathol 2004, 11:86-93. 10.1097/00125480-200403000-00002, 15090844.
14. Leong TY, Cooper K, Leong AS. Immunohistology: past, present, and future. Adv Anat Pathol 2010, 17:404-418. 10.1097/PAP.0b013e3181f8957c, 20966646.
15. Leong TY, Leong AS. How does antigen retrieval work?. Adv Anat Pathol 2007, 14:129-131. 10.1097/PAP.0b013e31803250c7, 17471119.
16. Siddiqui S, Rimm DL. Pre-analytic variables and phospho-specific antibodies: the Achilles heel of immunohistochemistry. Breast Cancer Res 2010, 12:113. 10.1186/bcr2782, 21176180.
17. Pinhel IF, MacNeill FA, Hills MJ, Salter J, Detre S, A'Hern R, Nerurkar A, Osin P, Smith IE, Dowsett M. Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer. Breast Cancer Res 2010, 12:R76. 10.1186/bcr2719, 3005722, 20920193.
18. Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998, 4:844-847. 10.1038/nm0798-844, 9662379.
19. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000, 80:1943-1949. 10.1038/labinvest.3780204, 11140706.
20. Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales AR. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol 2005, 123:21-27. 10.1309/4WV79N2GHJ3X1841, 15762276.
21. Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol 2010, 220:263-280. 10.1002/path.2629, 19927298.
22. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009, 360:790-800. 10.1056/NEJMra0801289, 19228622.
23. Reis-Filho JS, Weigelt B, Fumagalli D, Sotiriou C. Molecular profiling: moving away from tumor philately. Sci Transl Med 2010, 2. 47ps43.
24. Weigelt B, Reis-Filho JS. Molecular profiling currently offers no more than tumour morphology and basic immunohistochemistry. Breast Cancer Res 2010, 12(Suppl 4):S5. 10.1186/bcr2734, 3005725, 21172089.
25. Weigelt B, Mackay A, A'Hern R, Natrajan R, Tan DS, Dowsett M, Ashworth A, Reis-Filho JS. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol 2010, 11:339-349. 10.1016/S1470-2045(10)70008-5, 20181526.
26. Cleator SJ, Powles TJ, Dexter T, Fulford L, Mackay A, Smith IE, Valgeirsson H, Ashworth A, Dowsett M. The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis. Breast Cancer Res 2006, 8:R32. 10.1186/bcr1506, 1557729, 16790077.
27. Simon R. Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 2005, 23:7332-7341. 10.1200/JCO.2005.02.8712, 16145063.
28. Dupuy A, Simon RM. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst 2007, 99:147-157. 10.1093/jnci/djk018, 17227998.
29. Diamandis EP. Cancer biomarkers: can we turn recent failures into success?. J Natl Cancer Inst 2010, 102:1462-1467. 10.1093/jnci/djq306, 20705936.